Feline Cutaneous Lymphoma (Epitheliotropic and Non-Epitheliotropic)

Feline cutaneous lymphoma (FCL) is an uncommon but clinically significant neoplastic condition in which malignant lymphocytes infiltrate the skin, either primarily or as part of systemic disease. It is broadly classified into two major forms: epitheliotropic cutaneous lymphoma (ECL), in which neoplastic T-lymphocytes show a tropism for the epidermis and adnexal structures, and non-epitheliotropic cutaneous lymphoma (NECL), in which malignant lymphocytes (of either T-cell or B-cell origin) accumulate predominantly within the dermis and subcutis without epidermal involvement [2]. Skin tumors represent the second most common form of feline cancer after haematopoietic neoplasms, and cutaneous lymphoma—while uncommon—carries a guarded to poor prognosis [2]. The disease may remain localized to the skin or disseminate to regional lymph nodes, visceral organs, bone marrow, and peripheral blood, particularly in cases involving T-cell lineage [1].

The precise etiology of feline cutaneous lymphoma remains incompletely understood, and no single definitive cause has been established in the current literature. The disease arises from the clonal expansion of neoplastic lymphocytes within or involving the skin.

Epitheliotropic cutaneous lymphoma (ECL) is typically of T-cell origin and is characterized by migration of malignant T-lymphocytes into the epidermis, hair follicle epithelium, and adnexal structures—a behavior analogous to mycosis fungoides in humans. The underlying molecular triggers for this aberrant epidermotropism are not yet fully elucidated in cats, but are thought to involve dysregulated T-cell receptor signaling, altered cytokine microenvironments, and loss of normal apoptotic regulation.

Non-epitheliotropic cutaneous lymphoma (NECL) can originate from either T-cell or B-cell lineages [2]. B-cell NECL, as documented in reported feline cases, presents with multifocal dermal and subcutaneous nodular infiltrates composed of large, atypical lymphocytes without involvement of the overlying epidermis [2]. In disseminated T-cell NECL, neoplastic lymphocytes infiltrate the deep dermis and may extend to visceral organs, bone marrow, and blood [1].

Potential predisposing factors that have been discussed in the veterinary literature include:

• ·Advancing age: Most affected cats are middle-aged to geriatric (median age typically >10 years) [1][2]
• ·Concurrent immunosuppressive conditions: The reported association with diabetes mellitus in at least one documented case raises the question of whether immunocompromise may facilitate lymphoid neoplasia [1]
• ·Chronic antigenic stimulation: As with lymphomas in other sites, persistent immune stimulation from infections or inflammatory conditions may contribute to clonal lymphocyte expansion

The pathological sequence in disseminated T-cell NECL involves systemic spread to lymph nodes, spleen, liver, lungs, and bone marrow, where neoplastic lymphocyte infiltration disrupts normal hematopoiesis, potentially producing severe regenerative anemia through erythroid hyperplasia as a compensatory response [1].

Diagnosis of feline cutaneous lymphoma requires integration of clinical findings, hematological and biochemical data, histopathology, and immunophenotyping.

Clinical Evaluation

• ·Thorough physical examination noting distribution, morphology (macules, patches, plaques, nodules), and progression of skin lesions [1][2]
• ·Assessment for systemic involvement: peripheral lymphadenopathy, organomegaly, respiratory signs

Hematology and Serum Biochemistry

Relevant laboratory abnormalities that may be identified include:

• ·Complete blood count (CBC):
  • ·HCT (hematocrit): May be markedly decreased, consistent with severe anemia (regenerative anemia documented in disseminated T-cell NECL) [1]
  • ·WBC: Variable; atypical intermediate-to-large lymphocytes may be identified on blood smear in systemic disease [1]
  • ·PLT (platelets): May be decreased with bone marrow involvement
• ·Serum biochemistry:
  • ·ALB (albumin): May be decreased in chronic, debilitating disease
  • ·GLOB (globulins): May be elevated in some lymphoma subtypes due to inflammatory or paraneoplastic responses
  • ·ALT: May be elevated with hepatic infiltration
  • ·BUN/CREA: Elevation possible with renal infiltration or concurrent renal disease
  • ·Glucose: Hyperglycemia may be present in diabetic patients [1]

Bone Marrow Aspiration

• ·In disseminated disease, bone marrow aspirates may reveal marked erythroid hyperplasia and low numbers of atypical lymphocytes, confirming systemic involvement [1]

Cytology and Histopathology

• ·Fine-needle aspiration (FNA) of skin lesions or lymph nodes provides initial cytological assessment
• ·Excisional or punch skin biopsy is essential for definitive diagnosis; histopathology distinguishes ECL (epidermotropic lymphocyte infiltration) from NECL (dermal/subcutaneous infiltration without epidermal involvement) [2]
• ·NECL nodules typically demonstrate sheets or clusters of large, atypical lymphocytes in the dermis and subcutis [2]

Immunohistochemistry (IHC) and Flow Cytometry

• ·Critical for lineage determination (T-cell vs. B-cell) and classification [1][2]
• ·T-cell markers: CD3, CD4, CD8
• ·B-cell markers: CD20, CD79a, PAX5
• ·Immunophenotyping directly influences prognosis and treatment selection [2]

Imaging

• ·Thoracic radiography and thoracic CT: May reveal pulmonary infiltrates, bronchial pattern, or pleural effusion in disseminated disease [1]
• ·Abdominal ultrasound: Evaluates for hepatosplenomegaly, lymphadenopathy, and other visceral involvement [1]
• ·Advanced cross-sectional imaging (CT/MRI): Useful for staging the extent of systemic involvement [1]

Staging

Full staging workup—including CBC, biochemistry, urinalysis, lymph node cytology/biopsy, bone marrow aspiration, and imaging—is recommended to differentiate primary cutaneous disease from cutaneous manifestation of multicentric lymphoma.

Treatment of feline cutaneous lymphoma depends on the histological subtype (ECL vs. NECL), immunophenotype (T-cell vs. B-cell), extent of disease (localized vs. systemic), and the patient's overall health status.

Chemotherapy

• ·Multi-agent chemotherapy protocols (e.g., CHOP-based: cyclophosphamide, doxorubicin [hydroxydaunorubicin], vincristine [Oncovin], and prednisolone) are considered the standard of care for multicentric or disseminated lymphoma and may be applied in systemic NECL [1]
• ·Single-agent protocols (e.g., chlorambucil with prednisolone) are sometimes used in indolent or low-grade cutaneous presentations and may be better tolerated in geriatric patients
• ·Lomustine (CCNU): Has been used as a primary or rescue agent in feline epitheliotropic lymphoma, with responses reported in some cases

Immunotherapy and Targeted Therapy

• ·Retinoids (e.g., isotretinoin, etretinate): Used in ECL, particularly for exfoliative forms, with variable response
• ·Investigational targeted agents are under evaluation but are not yet standard of care in feline oncology

Surgical Management

• ·Surgical excision may be considered for solitary or well-circumscribed nodular NECL lesions, potentially combined with adjuvant chemotherapy
• ·Complete excision is rarely curative in multifocal disease [2]

Radiation Therapy

• ·Localized radiotherapy may provide palliative or curative-intent treatment for isolated cutaneous lesions

Supportive Care

• ·Blood transfusions: Indicated for severe regenerative anemia (packed cell volume markedly reduced), as documented in disseminated T-cell NECL cases [1]
• ·Glucose management: Diabetic cats require careful glycemic monitoring and insulin therapy management concurrent with lymphoma treatment [1]
• ·Antimicrobials: For secondary bacterial infections of ulcerated lesions
• ·Nutritional support: Maintenance of body condition in cachectic patients
• ·Analgesia and anti-pruritics: For patient comfort, particularly in pruritic ECL

The prognosis for feline cutaneous lymphoma is generally guarded to poor, particularly for disseminated or high-grade disease, though it varies significantly with subtype and extent of involvement.

• ·Non-epitheliotropic cutaneous lymphoma tends to carry a worse prognosis than ECL due to its often more aggressive behavior, higher histological grade, and greater propensity for systemic dissemination [2]. Multifocal B-cell NECL has been documented to progress rapidly, with affected cats typically surviving weeks to a few months without aggressive intervention [2].
• ·Disseminated T-cell NECL with bone marrow, pulmonary, and peripheral blood involvement represents an advanced-stage, life-threatening presentation [1]; in the reported case, the disease was progressive despite systemic spread being identified early, underscoring the grave prognosis of disseminated disease [1].
• ·Epitheliotropic cutaneous lymphoma (ECL): Survival times are variable. In cats, median survival times reported in the broader veterinary oncology literature range from a few months to over a year with treatment, depending on response to therapy, but can be very short in non-responders.
• ·The presence of systemic involvement (bone marrow, visceral organs, peripheral blood) is a significant negative prognostic indicator [1].
• ·Concurrent systemic diseases such as diabetes mellitus may further complicate management and worsen outcomes [1].

Important limitation note: The references cited above are primarily case reports and case series rather than large cohort studies. Formal population-level survival statistics (e.g., median survival times with confidence intervals, response rates by subtype) are not quantitatively reported in these references. Clinicians should consult current veterinary oncology textbooks and specialized literature for the most up-to-date survival data.

There are currently no known vaccines or proven preventive interventions specifically targeting feline cutaneous lymphoma. Because the etiology remains incompletely understood, definitive prevention strategies cannot be prescribed. The following general management recommendations may be considered based on current understanding:

• ·Regular veterinary examinations: Geriatric cats (>10 years) should undergo at least biannual wellness examinations, including thorough dermatological assessment, to facilitate early detection of suspicious skin lesions [1][2]
• ·Management of chronic diseases: Optimal control of concurrent conditions such as diabetes mellitus may help reduce the degree of immunosuppression that could theoretically facilitate lymphoid neoplasia [1]
• ·Minimizing chronic immunosuppression: Avoiding unnecessary long-term corticosteroid or immunosuppressive drug use where possible
• ·Environmental management: Reducing potential carcinogenic exposures (e.g., tobacco smoke, certain pesticides) is a general oncology recommendation, though specific links to FCL have not been established in the cited literature
• ·Early biopsy of persistent or progressive skin lesions: Rapid diagnostic evaluation of suspicious dermatological findings allows earlier intervention and potentially better therapeutic outcomes [2]